On behalf of the editorial team (Regina Herzlinger, Kevin Schulman, Lawrence Van Horn, and myself), I am delighted to welcome you to the current issue of HMPI. We are proud to publish another strong set of articles that help advance HMPI's vision: We draw from the research and experience of scholars and practicing leaders to provide insights for public and private health sector organizations around the world. This issue kicks off with a set of articles about a question that has huge topical importance: drug prices in the U.S. and elsewhere. This question never lurks far below the surface of political and industry discourse and the current U.S. administration is considering multiple initiatives that would rein in what it believes are excessive prices. The articles in this issue outline the nature of pharmaceutical markets, discuss alternative pricing systems, and consider how moral hazard that arises due to third party payment may contribute to escalating drug prices. The challenge here, of course, is to find a viable balance of costeffectiveness with continued development of innovative medicines that support health and healthcare in the U.S. and globally. Together, the articles provide a thoughtful base for considering mechanisms that will help find and maintain that balance.
